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Abstract
Objective: Despite the high prevalence of epilepsy in Africa, evaluation of epilepsy research trends on the continent is lacking. Without establishing effective
research, improvement in care for people with epilepsy cannot be effectively
strategized or targeted.
Methods: A scoping review of the peer-reviewed literature on epilepsy from
Africa (1989–2019) was conducted. The aim was to understand from this what
areas are well researched versus underresearched based on published epilepsy
topics.
Results: A total of 1227 publications were identified and assessed. A significant
increase in publications occurred over the 30 years assessed. African author leadership was evident in most reports. Nine countries had >50 publications identified; the remaining 45 countries had <50 or no publications. Research studies
were typically of lower quality (case series and observational studies). Research
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themes were more focused on clinical epilepsy (descriptive observational studies)
and social aspects (qualitative surveys). However, there were a number of unique
and strong themes, specifically for neurocysticercosis and nodding syndrome,
where strong research collaborations were evident, basic science understandings
were explored, and interventional models were established.
Significance: Despite Africa being the continent with the most countries, it is
lacking in the quantity, quality, and for some areas, relevance of research on
epilepsy. Targeted approaches are needed to upskill the strength of research undertaken with more basic science, interventional, and randomized controlled
studies. Themes of research need to promote those with unique African content
but also to align with current international research areas that have impact on
care delivery, such as epilepsy surgery and epilepsy genetics. For this to be possible, it is important to strengthen research hubs with collaborations that empower
Africa to own its epilepsy research journey.
KEYWORDS

Africa, epilepsy, low-and middle-income countries, research, scoping review, treatment
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I N T RO DU CT ION

Low-and middle-income countries, especially those in
Africa, bear the highest burden of epilepsy.1–4 A recent
global burden of disease study reported that the decline
in numbers of those living with epilepsy in high-income
countries (HICs) is not evident for low-income regions,
and particularly in sub-Saharan Africa.4 The median prevalence of active epilepsy in HICs was 4.9 per 1000 compared to 12.7 per 1000 in rural areas of resource-limited
countries.3–5
This significant disparity in numbers and outcomes
can be attributed to increased prevalence of risk factors for
epilepsy in resource-limited countries that include infectious diseases, preventable brain injuries, and poor access
to and capacity of health care services.2,3
Despite the high prevalence, analysis is lacking that
critiques epilepsy research trends in Africa. A recent focused review exploring epilepsy research trends in children with epilepsy from Kenya identified only 35 research
papers from the region between 2004 and 2019.6 Despite
the exponential increase in epilepsy genetics research
across resource-equipped settings, such data are largely
unavailable in Africa.7 HICs have documented trends in
epilepsy research and patient experience that have directly led to improved epilepsy management and outcome
in these settings.
Understanding the current trends in epilepsy research
in Africa is important to identify regionally relevant focus
themes as well as to strategize critical gaps in research
that are necessary to optimize epilepsy care.8 Expanding

Key Points
• There has been a significant increase in the
number of epilepsy publications originating
from Africa during 1989–2019
• West Africa had the highest proportion of publications, and Central Africa had the least, with
significant variation evident within regions
• Fourteen African countries had no identified
publications on epilepsy over the study period
• Basic science themes and interventional study
approaches were evident in publications on
neurocysticercosis and nodding syndrome
• The majority of the publications focused on
clinical and social aspects of epilepsy, with an
increase in qualitative studies over time

on existing knowledge of the epidemiology of epilepsy in
Africa would be a first step in laying the foundation for
robust advocacy within the region.5
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MATERIALS AND METHO D S

We applied the Joanna Briggs Institute's approach for
conducting a scoping review,9 which is a systematic five-
step approach to searching, screening, and reporting. The
steps included (1) identification of the research questions;
(2) identification of relevant databases; (3) study selection;
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(4) data extraction; and (5) result interpretation, summarization, and dissemination. A scoping review of literature
on epilepsy from Africa published between 1989 and 2019
was conducted. This timespan was considered adequate to
understand the trends of epilepsy research in Africa. The
concept of an African study was regarded as a study based
in an African country or countries on an epilepsy-related
topic. Collaborative studies with additional non-African
countries were included, but the focus of the data collection was on epilepsy in Africa.
This report was undertaken under the auspices of
the Pediatric Commission of the International League
Against Epilepsy (ILAE). The ILAE has six regional commissions, of which Africa falls into two, specifically the
African Commission and the Eastern Mediterranean
Commission. The working group for the task force elected
to be inclusive of all countries in Africa for the report to be
representative of the whole African continent. However,
regional assessments were made, for example, specific to
activities in North Africa, East Africa, sub-Saharan Africa,
and so on.
To guide the search strategy and ensure that a broad
range of literature was captured in this study, two research
questions were formulated, namely: What is the epilepsy
research conducted in Africa? What areas are underresearched based on published epilepsy topics? We were
particularly interested in the types of research published,
what the focus of the publications were, and the trends in
frequency of these publications over time, to identify areas
that were adequately represented and those that were not
in comparison with international publication trends. In
addition, we sought to determine regions with consistent research teams generating high-quality studies led
by African researchers and to understand the evolution
in funding grants awarded to African centers. A scoping
review was hence selected as the most appropriate methodology to address these questions.
A computerized search was conducted in the following
databases without methodological restrictions between
January 1, 1989 and March 31, 2019: Embase, MEDLINE,
and AJOL (African Journals Online). The search strategy
included the following keywords: seizures, convulsions,
epilepsy, epilep*, Africa, and specific African country
names (such as Egypt, Tanzania, etc.) and regions (e.g.,
North Africa, West Africa). We included all study designs
published between 1989 and 2019 in English, French, and
Portuguese. We combined keyword terms and phrases
related to epilepsy and Africa, including epidemiology,
management, and outcomes, to identify the studies. Team
members then tested our search terms, and consensus was
attained regarding the search strategy (Appendix S1). The
reference list of review studies was examined to determine
whether other studies were not captured through the
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electronic search. Suitable titles were subsequently added
if they met the criteria for review.

2.1

|

Study selection

Seven researchers independently screened papers by
title and abstract and identified those for full text review in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-
Analyses (PRISMA)
extension for scoping reviews (Appendix S2).10,11 Where
there was lack of clarity regarding a specific study, this
was discussed at the regular team meetings, and a consensus regarding inclusion was arrived at. Following evaluation, data were extracted and entered into the Research
Electronic Data Capture (REDCap) platform (Vanderbilt
and National Institutes of Health)12 hosted at the Aga
Khan University to allow all investigators to contribute to
data entry, extrapolation, and analysis. All articles were
imported into both Endnote and REDCap. Duplicates
were removed. Three authors (P.S., J.S., and J.W.) rechecked the data entered for completeness and accuracy.
We included peer-reviewed journal articles as well as case
series with data from more than five cases, comparison
studies, observational studies, surveys, and randomized
control trials.
The following types of publication were excluded: conference abstracts and posters, case reports and series with
fewer than five cases, commentaries, policy briefs, editorials, opinion pieces, and debates. Also excluded were
studies that did not contain extractable data on an African
country, region, or the whole continent/subcontinent;
studies of acute symptomatic seizures in nonepileptic patients; and studies that did not contain basic science or
patient-derived data related to epilepsy.

2.2

|

Data extraction

The data extraction for this study is summarized below.

2.3

|

Data synthesis and dissemination

All studies included in this scoping review were analyzed
using descriptive statistics and thematic analysis. Results
were organized in tables and charts and presented into
themes that reflect the review objectives. Tables were
used to illustrate how epilepsy research has evolved from
January 1, 1989 to March 31, 2019 in terms of themes, research design, authorship, and geography. The PRISMA
flow chart (Figure 1) was used to summarize the included
and excluded research studies. Supporting figures were
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FIGURE 1

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart

developed to present the synthesis with a focus on which
to draw future research implications.

framework, and a DOI was assigned (DOI 10.17605/
OSF.IO/6TGKM).

2.4 | Ethics approval and protocol
registration

2.5

Ethical approval was not required, as no primary
data were collected. The protocol for this scoping
review was publicly published on the open science

|

Statistics

Statistical tests were performed using SPSS statistical software version 20.0 (IBM). Categorical data were presented
as frequencies and percentages. Chi-
squared test was
used to compare the frequencies and percentages among
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different groups, and Kruskal–Wallis test was used to
compare between different time frames.

3

|

R E S U LTS

A total of 3122 studies were identified through the database search. Following screening, studies were excluded
as follows: 254 were conference abstracts, and 628 did
not contain extractable data from an African country. At
evaluation, 121 studies investigated acute symptomatic
seizures in nonepileptic patients, 378 were published before 1989, and 514 did not contain basic science or patient-
derived data on epilepsy or reported data from fewer than
five cases. None of the Portuguese language studies met
the inclusion criteria. The remaining 1227 studies were
included in the scoping review (Figure 1 shows PRISMA
study flow chart).

3.1 | Publication characteristics of
epilepsy research in Africa
Location, funding, and authorship characteristics are
included in Table 1. There has been a steady increase
in publications, with the majority of reports between
2013 and 2019 (Figure 2A,B). Over three consecutive
time frames, statistical difference (p = .001) was evident
for the numbers of publications during 2009–2019 (801,
65%, 95% confidence interval [CI] = 62.5%–67.9%) compared to 1989–1998 (125, 10%, 95% CI = 8.6%–12.0%)
and 1999–2008 (301, 24%, 95% CI = 22.2%–27.0%). The
period with the least published research was 1989–1998,
specifically 1989, with a total of five published studies. Of
the 1227 published studies, 824 (67%, 95% CI = 64.4%–
69.8%) studies were published in international journals,
whereas 403 (33%, 95% CI = 30.2%–35.6%) studies were
published in African journals, with little change in this
over the years.
A total of 746 (61%) studies were exclusively written
by African authors, whereas 81 (7%) studies did not include any African authors. A total of 762 (62%) studies
had an African author in both the first and last authorship
position, 257 (21%) studies had an African author in the
first or last position, and 208 (17%) studies did not have an
African author in either first or last position (Figure 2A,B).
Fourteen African countries had no identified publications on epilepsy over the study period (Angola, Republic
of Congo, Chad, Comoros, Cape Verde, Djibouti, Eritrea,
Equatorial Guinea, Lesotho, Western Sahara, Somaliland,
Somalia, Sao Tome and Principle, and Swaziland). The
heat map of Africa (Figure 3A) demonstrates the proportions of reports in the remaining 40 countries. Figure 3B

  

|

5

illustrates the trends in the most prolific countries with
>50 publications over the consecutive decades.
Overall, West Africa had the highest proportion of research conducted (n = 428, 35%), whereas Central Africa
had the least (n = 90, 7%). Multicenter African studies accounted for 27% (n = 333). In West Africa, the majority of
studies (n = 274, 22%, out of 1227 for all of Africa) took place
in Nigeria, whereas Niger, Liberia, and Gambia only had one
study published from each country. In Central Africa, the
majority of studies (n = 56, 5%) were conducted in Cameroon
compared to four studies from the Central African Republic.
In East Africa, the majority of studies (n = 80, 7%) were published from Uganda, followed by Tanzania and Ethiopia,
whereas Rwanda had the lowest number of studies with
only seven identified. In North Africa, 72 (6%) studies were
conducted in Egypt, whereas the fewest studies were conducted in Libya, with four reports. Lastly, in Southern Africa,
South Africa had the most studies (n = 119, 10%), whereas
Namibia, Reunion Island, and Botswana had the fewest studies published, with two each.
Of the 361 funded studies, 232 (64%) studies were
externally funded such as via seed grants and contributions in kind of time and effort, whereas 110 (30%) studies were funded through research grants, 15 (4%) studies
were funded from various associations (e.g., the ILAE,
International Child Neurology Association, International
Brain Research Organization), and only four among these
studies were related to sponsored pharmaceutical work.
Regarding types of studies, descriptive and observational studies dominated, with 161 (13%) case series, 572
(47%) observational studies, 286 (23%) surveys, and 78
(6%) reviews. There were 120 (10%) comparison studies
and only 10 (1%) randomized controlled trials.
Subject and research characteristics of included studies are reported in Table 2. Research themes are reported
in Figure 4. Of the 1227 studies, there were 694 (56%)
descriptive clinical epilepsy studies, 314 (26%) studies
analyzing social components related to individuals with
epilepsy, 90 (7%) interventional studies, 74 (6%) basic science studies, 47 (4%) diagnostic studies, and eight (1%)
systematic reviews about epilepsy. Some subjects were
frequently investigated focus areas, namely etiology
(n = 266, 22%), clinical features (n = 280, 23%), epidemiology (n = 196, 16%), and drug management findings
(n = 147, 12%). Conversely, epilepsy surgery (n = 15, 1%),
neuroimaging (n = 56, 5%), genetics (n = 50, 4%), long-
term outcomes (n = 73, 6%), and electroencephalographic
features (n = 77, 6%) were explored less frequently. There
was a balance between studies specifically investigating
adults (n = 345, 28%) and children (n = 332, 27%), with
452 (37%) reports including all ages. There were 18 (2%)
studies on women. A total of 472 (38%) studies noted
unique Africa themes (Table 3).
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TABLE 1

Data extraction framework

Key domains

Description

Year published

Year of publication

Type of journal

International
African

Author

Indicate where the lead author is based (e.g., African based in Africa, non-African in Africa, African based
outside of Africa, and non-African not based in Africa)

Number of African authors

Percentage of authors of African origin in each study

Author composition

Single author or multiple authors on the paper

Study location

The region the study was completed in and the respective countries within the region

Type of study

Case seriesa
Comparison study
Observational study
Survey
Randomized control trial
Review article

Research theme or focus

1.
•
•
•
•
•
•
•
•
•
1.
•
•
•
1.
•
•
•
•
•
•
•
•

Clinical epilepsy
Epidemiology—prevalence and incidence of epilepsy of the study participants
Etiology
Clinical features
EEG features
Neuroimaging
Genetics
Drug management
Epilepsy surgery
Long-term outcomes
Research subject characteristics
Children, adults, women, or mixed populations
Number of study subjects
Comorbidities (i.e., anxiety, ADHD, ASD, learning disability)
Etiologies of special interest to Africa
HIV
Sickle cell disease
Nodding syndrome
Neurocysticercosis
Tuberculosis
Cerebral malaria
Trauma
Birth asphyxia

Funding for research

Pharma driven
Research grants
Association funding (i.e., ILAE)
Other

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; EEG, electroencephalographic; ILAE, International League
Against Epilepsy.
a

Data from more than five cases.

3.2

|

Topics of special relevance to Africa

Among the 194 studies describing etiologies of special interest to Africa, nodding syndrome (n = 53, 27%), neurocysticercosis (n = 65, 34%), cerebral malaria (n = 15, 8%),
and human immunodeficiency virus (n = 12, 6%) were

key themes. Birth asphyxia (n = 2), sickle cell disease
(n = 1), tuberculosis (n = 1), and trauma (n = 1) had less
frequent reports. The following topics expand on areas of
special relevance to Africa, illustrating that unique, targeted, and evolving research can be done well, especially
in the African setting.

SAMIA et al.
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(A)

(B)

F I G U R E 2 (A) There was a statistically significant difference in publications across three time frames but with no proportional variance
in lead authorship positions. (B) Detailed illustration of trends in publication numbers and African lead authorship between 1989 and 2019

3.2.1

|

Traditional healers

Studies relating to traditional healers frequently reported
that people with epilepsy chose traditional healers over
health care professionals as their preferred practitioners
to manage their epilepsy. This was often driven by beliefs about the underlying cause of the epilepsy, as well
as traditional healers having more cost-effective payment
methods and better availability.13–17 Trends in research

over time moved toward working with traditional healers
to build on resources to support people with epilepsy18–20
and to develop models to improve pathways to care.21–25
Traditional healers are notable for their cultural understanding and use of plants in the management of epilepsy
as well their ability to provide detailed clinical descriptions of event semiology.26,27 Exploring the preferred use
of traditional healers led Millogo et al. to note that traditional healers can impart useful messages, namely their

8
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(A)

(B)

F I G U R E 3 (A) Heat map to illustrate the range of publications on epilepsy generated over 1989–2019 in African countries. (B) African
countries with >50 publications on epilepsy topics, illustrating the increase in publications with each decade, especially 2009–2019
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T A B L E 2 Location, funding, and author characteristics of
included studies
Characteristics, N = 1227

n (%)

Year published
1989–1999

146

2000–2009

328

2010–2019

753

Type of journal
African journal

403 (33)

International journal

824 (67)

Research funding, n = 361
Pharma driven

4 (1)

Research grant

110 (30)

Associations

15 (4)

Other

232 (64)

Region of Africa published from
East Africa

292 (24)

West Africa

428 (35)

Sub-Saharan Africa

177 (14)

Central Africa

90 (7)

North Africa

181 (15)

Multisite

177 (14)

Authors of study
Multicenter

406 (33)

Africa and other countries

543 (44)

Other

278 (23)

Authorship of African authors
Not first nor last

208 (17)

First or last

257 (21)

First and last

762 (62)

advice to people with epilepsy to stay away from fires and
to avoid eating pork.28 Although limited at many other
treatment levels of epilepsy care, implementation of these
two aspects would have significant impact for prevention
of seizure injury and prevention of neurocysticercosis in
endemic regions.

3.2.2

|

Ethnopharmacology

The study of ethnopharmacology is very exciting in the
African context, with overlap in the field of traditional
healers' practice, as this group often has extensive knowledge of and is involved in the clinical application of plant-
based products for people with epilepsy.26,27 Early animal
models (typically mice) were used to explore the role of
products such as the West African black pepper water extract29 and ethanolic extract of the leaves of Maprounea

|
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africana.30 Sehlare sa Seebana is a trditional Nothern
Sotho herbal remedy for epilepsy which consisted of aqueous and ethanol extracts of six plants adminstered by inhalation of smoke. This product was effectively tested in
a γ-aminobutyric acid type A (GABAA)–benzodiazepine
receptor binding assay.31 Rhus chirindensis stem-bark extract is used in South African traditional medicines and
produces its antiseizure effect by enhancing GABAergic
neurotransmission and/or action in the brain. The authors
proposed that the plant could be a natural supplementary remedy in the management of childhood seizures.32
Searsia dentata and Searsia pyroides are used in traditional South African medicine to treat convulsions and epilepsy. In a mouse model study, the N-methyl-D-aspartate
(NMDA) receptor antagonistic effect was demonstrated
for the crude ethanolic extracts of these two South African
medicinal plants.33 Another study on the same plant species, collected from the Botanical Garden at the University
of KwaZulu-Natal, confirmed the specificity of the plants
and justified their use in traditional medicine for the
treatment of epilepsy.34 Nigerian studies on the aqueous
leaf extract of Albizia glaberrima found that the product
enhanced GABAergic inhibitory actions35 and suggested
that the methanol leaf extract of Laggera aurita possesses
antiseizure properties.36 A study from Cameroon found
that Senna spectabilis possesses antiseizure activity, hypothesizing that the plant decoction could interact with
GABAA complex receptor probably at the GABA and benzodiazepines sites.37 Overall, although there is common
and ongoing use of plant products by traditional healers
for people with epilepsy, research on this at a scientific
level continues to be on mouse models.30–36 In settings
where access to antiseizure medications is often challenging, to identify effective and sustainable local remedies
would be ideal.

3.2.3

|

Nodding syndrome

Over the past decade there have been >50 reports on nodding syndrome, a condition that has undergone unique
clinical, electroclinical, biomedical, and epidemiological
assessments.38–41 This condition is prevalent in specific regions of Africa, especially Uganda, Tanzania, and Sudan,
with variations in phenotypic expression.42 Affected children have an occasional nodding of the head, which can
correlate with seizure activity and is often triggered by
eating.43
Although the pathogenesis has not been completely delineated, a role of Onchocerca volvulus, the parasitic filarial
worm responsible for river blindness that is highly endemic in these areas, is suspected. The result of the careful
correlation of nodding syndrome with high prevalence of

10
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F I G U R E 4 Regional breakdown of
research themes illustrating across Africa
the focus on descriptive clinical epilepsy
studies and research related to social
issues compared to the more limited focus
on diagnostic, interventional, and basic
science research. SSA, sub-Saharan Africa

onchocerciasis has led to community-directed treatment
with ivermectin, such that there was a significant decrease
in the incidence of nodding syndrome between 2012 and
2017.44 Similar conclusions were drawn from community
studies in Cameroon.45,46 More recent reports have highlighted the correlation of malaria with disease expression
and outcome in children with nodding syndrome.2,47
This led to promotion of intervention with doxycycline
to eradicate or prevent malaria in children with nodding
syndrome.47,48 Nodding syndrome is also considered to be
a neuroinflammatory disorder, triggered by antibodies to
O volvulus or its symbiont, Wolbachia, which cross-react
with human neuron proteins. Doxycycline may have a
treatment role, as it is hypothesized to kill Onchocerca
through effects on Wolbachia.47
Numerous other etiologies have been explored, such as
autoimmune encephalitis, which was considered unlikely
based on negative anti-NMDA and anti-voltage-gated potassium channel receptor antibodies in affected patients.49
Metabolic derangements were not evident50 as a cause,
nor was the consumption of mycotoxins in contaminated
foods.51
As the course and phenotype of the disease was understood, symptomatic guidelines were developed by the leading African clinicians and successfully implemented.52
The debate about the correlation of the movements (head
nods) and seizures was carefully delineated via neurophysiological studies.53 The social challenges and burden
of disease were noted as well as caregiver perceptions and
the involvement of traditional healers.54

3.2.4

|

Neurocysticercosis

Neurocysticercosis is also an established public health
challenge affecting regions in Africa and beyond. It is related to poor pigpen management and contamination of

food products. Epidemiological studies confirmed that in
some regions, especially rural locations, neurocysticercosis was the predominant cause of epilepsy in adults.55,56
Studies confirmed the high number of disability-adjusted
life-years impacted by neurocysticercosis.57,58
Interventional public health programs have been implemented and identified further challenges to change
community practices.59 Serial vaccination of pigs with
the TSOL18 vaccine and medication with oxfendazole
eliminated Taenia solium transmission by pigs in a study
in Uganda.60 The World Health Organization (WHO) includes addressing T solium as one of the 2030 goals, noting the debate between biomedical interventions (human
and pig treatment and pig vaccination) compared to improved husbandry, sanitation, and meat inspection with
insight into the need for sustainable solutions for severely
resource-
constrained endemic settings.61 A computer-
based T solium educational program, "The Vicious Worm,"
was rolled out to primary school students in Zambia and
led to significantly increased knowledge after the educational component, particularly regarding parasite transmission and disease prevention.62
Despite the public health awareness of the spread of
cysticercosis, much remains unknown about many key
pathogenic aspects of the disease, including how cerebral infection with T solium results in the development of
seizures.63 Eloquent basic science research suggests that
Taenia larval acetylcholinesterases can interfere with cholinergic signaling in the host, potentially contributing to
pathogenesis in neurocysticercosis.64

4
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DISC USSION

This scoping review addresses the trends of data published on epilepsy in Africa over a 30-year period to identify the number of publications, the predominant themes

SAMIA et al.

TABLE 3
studies

  

Subject and research characteristics of included

Characteristics, N = 1227

n (%)

Type of study
Case seriesa

161 (13)

Comparison study

120 (10)

Observational study

572 (46.5)

Survey

286 (23)

Randomized control trial

10 (1)

Review article

78 (6.5)

Theme of research
Clinical epilepsy–descriptive

694 (56.5)

Diagnostic

47 (4)

Interventional

90 (7)

Social

314 (25.5)

Systematic review

8 (1)

Basic science

74 (6)

Clinical epilepsy
Epidemiology

196 (16)

Etiology

266 (22)

Clinical features

280 (23)

EEG features

77 (6)

Neuroimaging

56 (4.5)

Genetics

50 (4)

Drug management

147 (12)

Epilepsy surgery

15 (1)

Long-term outcomes

73 (6)

Research subjects
Children

332 (27)

Adults

345 (28)

Women

18 (1.5)

Children and adults

452 (36.5)

Etiologies of special interest to Africa, n = 194
HIV

12 (6)

Sickle cell disease

1 (.5)

Nodding syndrome

53 (27)

Neurocysticercosis

65 (33.5)

Tuberculosis

1 (.5)

Cerebral malaria

15 (8)

Trauma

1 (.5)

Birth asphyxia

2 (1)

Other

54 (28)

Abbreviations: EEG, electroencephalographic; HIV, human
immunodeficiency virus.
a

Data from more than five cases.

published, characterization of authorship, and where research is occurring, as well as the gaps in research topics
and locations. Epilepsy in Africa is a significant challenge,
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particularly in children, who make up at least 50% of
the population in most regions.2–4 Compared to better
resourced regions, availability of data on epilepsy from
Africa is wanting, and strategies to reverse these trends
are needed urgently.65,66
Africa has many unique challenges related to the prevention and management of epilepsy, ranging from low
availability of skilled health workers, the smallest global
proportion of neurologists, poor availability of efficacious
antiseizure medications with fewer side effects, low public awareness of epilepsy and resultant stigma, and significant barriers to research.65–68
It is reassuring to see the steady increase in publications, especially over the past decade, and that two thirds
of the reports are included in peer-review international
journals. In addition, African researchers appear to be taking the lead in the majority of reports, although the ratio
of African lead versus non-African lead has shown little
variance over the past 30 years. Some regions and countries are leaders in this and could represent research hubs
and focal areas to be pivotal in upscaling epilepsy research
in the future. This is especially the case for Nigeria, South
Africa, Uganda, Egypt, Tanzania, Cameroon, Ethiopia,
Tunisia, and Kenya. It is worrying that many countries
had either no or minimal research publications. Some regions tend to publish on relatively narrow themes and are
yet to branch out into broader epilepsy themes. However,
the expertise evident from these groups, for example,
nodding syndrome, illustrates how a uniquely African
condition can be explored from bench to bed, resulting
in effective interventional studies and in real change in
practice.44–46,48
Some 30% of the studies were supported by diverse
funding resources. In the setting of scarce resources and
busy clinical practices, access to funding support can be
critical to enable study completion. Similarly strengthening collaborations both across Africa and with international colleagues can lead to innovative and effective
outcomes. This includes assistance with the development
of study methodology, meticulous data capturing, and
accurate analysis and interpretation of findings. It is imperative that these collaborations are also learning and
training opportunities that consistently build the capacity
at the level of the African center.66
The quality of the research was of concern but not surprising based on the resource constraints. Most studies
were observational and often survey based. There were
few randomized controlled trials. Interventional studies
were scarce, and much of the research was driven by clinical epilepsy descriptions (e.g., etiology, clinical profiles,
and diagnostics). There were some very strong studies addressing epidemiology that had critical implications for
confirming the burden of disease in regions,3,5,69 as well

12

|

  

as large community-based studies exploring expression of
key diseases such as nodding syndrome and prevalence of
onchocerciasis.70,71 However, these studies tended to be
the exception, and compared to activity across resource-
equipped settings, the overall quality of the studies was
not comparable. Further, internationally topical epilepsy
research areas, such as epilepsy surgery and genetics, were
scarce, reflecting the limited access to these resources
across the continent.72,73 The importance of region-
specific genetic studies in epilepsy is well understood, and
with the significant genetic diversity represented on the
continent, genetic studies in epilepsy would foster the possibility of precision medicine, with targeted interventions
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for patients, as well as potentially contributing to further
understanding of the etiology of epilepsy in this region.
There is a high burden of brain injury in Africa, especially
for children, resulting in structural insults that often have
lesional implications, for which epilepsy surgery may be
remedial and have significant impact on resolution of epilepsy for these patients.
The data in Figure 5A illustrate the limitations in H
index for countries in Africa (neuroscience papers published 1996–2020). Compared to H indexes for combined
regions, Africa is second to last despite having the most
countries (Figure 5B). The Organization for Economic Co-
operation and Development combined 34 of the wealthiest

(A)

(B)

F I G U R E 5 (A) H index for countries in Africa from neuroscience papers published 1996–2020. Accessed at https://www.scimagojr.
com/countryrank.php?region=Africa, September 25, 2021. (B) H indexes of Africa other regions of the world, demonstrating that Africa is
second to last, despite having the most countries. Furthermore, the combined resource-equipped countries of the Organization for Economic
Co-operation and Development (OECD) have the highest H index. Accessed at https://www.scimagojr.com/countryrank.php?area=2800,
September 25, 2021
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high-income countries, which through this collaboration
work together with governments, policymakers, and citizens on establishing evidence-based international standards and finding solutions to a range of social, economic,
and environmental challenges. It is striking that this well-
resourced collection achieved the highest combined H
index.
As illustrated, Africa has some truly unique areas
of research, namely nodding syndrome and neurocysticercosis, which have included basic science and
laboratory-based analysis, epidemiological studies, and
subsequently interventional research leading to disease-
changing outcomes. Africa-based studies with strong international collaboration on nodding syndrome illustrate
an effective model that encompasses understanding disease expression and epidemiology, exploring the etiology
in depth, reviewing biomedical markers, understanding the socioeconomic implications, and implementing
pathways to both treatment and prevention. In similar
fashion, research on neurocysticercosis spans the range
of bench to bedside interventions as well as the community and socioeconomic aspects of the condition, which
has led to preventive efforts and formulation of effective
evidence-based management of epilepsy resulting from
neurocysticercosis.
The African setting carries a significant burden of disease from stigma and has undertaken extensive research
into this area and various approaches not just to measure the extent of the issue but also the effective models
of intervention to lead to change.8,74–77 The continent is
also well placed for exploring novel approaches to disease
that may not be acceptable in resource-equipped settings;
these could include a role for traditional healers21 as well
as ethnopharmacology and the field of neuropharmacognosy.36,37,65,78 Not surprisingly, almost half the reports on
specifically African themes addressed these high-burden
etiologies and social challenges for people with epilepsy.
Overall, the focus of reports for minority groups was
disappointing, with less than one third of the studies
addressing children specifically and very few related to
women with epilepsy.
Developing successful research programs that progress
beyond preclinical and observational studies is challenged
by many barriers in the African setting.66 These barriers
and potential solutions are addressed in the WHO/ILAE
report, specifically the chapter, “Research on Epilepsy.”79
The conceptual model devised by Franzen et al. featured
a three-pronged approach to develop sustainable health
research capacity in low-and middle-income countries.66
This focused on the needs of the individual, namely being
aware of research and trials, becoming motivated to lead
or work on trials, gaining knowledge and skills through
this process, and being able to take on trial leadership
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capabilities. At an operational level, these researchers and
other stakeholders should be able to form collaborations,
as well as acquire resources inclusive of trial operations
and implement relevant policy. The combined result
would enable strengthening at the macro and institutional
level with national grants and the expansion of networking platforms.
Despite some innovative researchers, basic science
research was proportionally low, and is a key area that
needs to be promoted. There are hubs of activity across
Africa, and the International Brain Research Organization
(IBRO) has further facilitated neuroscience in the African
region via the Society of Neuroscientists of Africa
(SONA), especially with the development of neuroscience training schools in Morocco and South Africa. The
founding of the SONA in 1993 opened exciting avenues
for upscaling African neuroscience research.65 The IBRO
provided critical support to the establishment and growth
of the SONA through conference and workshop support
as well as research fellowship opportunities. Various other
groups have been critical in supporting the advance of
African neuroscience, including the International Child
Neurology Association, ILAE, International Society for
Neurochemistry, National Institutes of Health, World
Federation of Neurology, and World Federation of
Neurosurgical Societies. Although this international support remains essential, African neuroscientists have a role
in engaging in policy and decision-making to persuade
governments to fund studies that address the unique regional needs in Africa.
Basic neuroscience research on local African fauna
and animal models of brain disorders offers novel and
innovative opportunities. This has supported the field of
neuropharmacognosy and the implications for disease-
modifying benefits of administering plant extracts to experimental animals.80

5 | STRENGTHS AND
LIMITATIONS OF THIS STUDY
This scoping review only synthesizes research publications over 30 years (1989–2019). There may be equally
important articles before this period or published after
this period. Research publications in other languages (i.e.,
those outside of English, French, and Portuguese) were not
used but may contain valuable information. However, the
main languages spoken in Africa are English and French,
with six countries speaking Portuguese. The keywords
used were broad and may not have identified specialized
studies. Regardless, this study will serve as a benchmark
for future epilepsy research in Africa. Finally, this study
having only one lead reviewer for individual papers is a
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limitation that may have had an impact on the quality of
the data collected.
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CO N C LUSION S

Epilepsy research in Africa has increased over the past
30 years, but there remains a great need to enhance the
capacity of the region both for the quality of the studies
and to encompass broader relevant areas. This would include more research focused on vulnerable groups, such
as children, women, and the elderly, and increasing high-
quality interventional studies to implement change in
practices for high-burden areas, as successfully illustrated
for nodding syndrome and neurocysticercosis, in addition to increasing research into areas underresearched
and still relevant, such as the role for epilepsy surgery
and the expression of epilepsy genetics in the region.
For this to be possible, although strong international collaboration remains essential and joint funding projects
should be promoted, the lead for these studies should
come from Africa, led by Africans. To enable this, training is critical for neuroscientists and clinicians spanning
from the laboratory to the clinical setting. In line with the
International Global Action Plan for Epilepsy and other
Neurological Disorders, Africa should increase its footprint by significantly upscaling epilepsy research within
Africa, by Africans. Only with this model can relevant,
viable, and sustainable practice change be implemented.
As stated by Bentivoglio et al., have powerfully and rightfully advocated for the need to have African problems resolvedthrough goal-directed basic neuroscience research
conducted in Africa to addressregion specific disorders.81
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SUPPORTING INFORMATION
Additional supporting information can be found online
in the Supporting Information section at the end of this
article.
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